Shire CFO Graham Hetherington to step down

13 February 2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that chief financial officer Graham Hetherington has decided to step down from the company.

The Board has agreed that Mr Hetherington (pictured) will step down from Shire’s Board of Directors on March 1. Shire’s Senior Vice President and Group Financial Controller, James Bowling, will be appointed as interim Shire CFO with effect from that date. Shire will start immediately a global search for Mr Hetherington’s successor.

Mr Bowling joined Shire in 2005 and has been a key leader in Shire’s finance team for the past nine years. He led Shire's financial reporting, financial planning and analysis, and treasury and insurance teams. As part of his role, Mr Bowling has had regular interaction with the company's Board of Directors, in particular supporting the Audit, Compliance & Risk Committee and the Remuneration Committee.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK